{"id":251621,"date":"2021-06-10T00:00:00","date_gmt":"2021-06-10T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/products\/research-reports\/report\/epidim0079-biopharma-crohns-disease-epidemiology-americas\/"},"modified":"2026-03-31T10:43:10","modified_gmt":"2026-03-31T10:43:10","slug":"epidim0079-biopharma-crohns-disease-epidemiology-americas","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidim0079-biopharma-crohns-disease-epidemiology-americas\/","title":{"rendered":"Crohn&#8217;s Disease &#8211; Epidemiology &#8211; Americas"},"content":{"rendered":"<p>Clarivate Epidemiology&#8217;s coverage of Crohn&#8217;s disease comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of Crohn&#8217;s disease for each country, as well as annualized case counts projected to the national population.<\/p>\n<p>Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets of the United States, Europe and Japan, and 10 years for the other countries covered in this report.<\/p>\n<p>Clarivate Epidemiology&#8217;s Crohn&#8217;s disease forecast will answer the following questions:<\/p>\n<ul class=\"round-bullets\">\n<li>How will changes in the levels of exposure to known risk or protective factors affect the number of people living with a diagnosis of Crohn&#8217;s disease?<\/li>\n<li>In developing countries, what impact will economic growth and development have on the number of people diagnosed with Crohn&#8217;s disease per year?<\/li>\n<li>Of all people diagnosed with Crohn&#8217;s disease, how many in each country across the major mature pharmaceutical markets are drug-treated?<\/li>\n<li>How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of Crohn&#8217;s disease over the forecast period?<\/li>\n<\/ul>\n<p>All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.<\/p>\n<p>In total, Clarivate Epidemiology forecasts 15 Crohn&#8217;s disease patient populations, as follows:<\/p>\n<ul class=\"round-bullets\">\n<li>Diagnosed prevalent cases.<\/li>\n<li>Diagnosed incident cases.<\/li>\n<li>Diagnosed drug-treated (acute setting) prevalent cases.<\/li>\n<li>Diagnosed non-drug-treated (acute setting) prevalent cases.<\/li>\n<li>Diagnosed drug-treated (maintenance setting) prevalent cases.<\/li>\n<li>Diagnosed non-drug-treated (maintenance setting) prevalent cases.<\/li>\n<li>Diagnosed B1 (nonstricturing, nonfistulizing) prevalent cases.<\/li>\n<li>Diagnosed B2 (stricturing) prevalent cases.<\/li>\n<li>Diagnosed B3 (penetrating) prevalent cases.<\/li>\n<li>Diagnosed L1 (terminal ileum) prevalent cases.<\/li>\n<li>Diagnosed L2 (colonic) prevalent cases.<\/li>\n<li>Diagnosed L3 (ileocolonic) prevalent cases.<\/li>\n<li>Diagnosed prevalent cases in remission.<\/li>\n<li>Diagnosed prevalent cases with low activity.<\/li>\n<li>Diagnosed prevalent cases with high activity.<\/li>\n<\/ul>\n<p>Note: coverage may vary by country.<\/p>\n","protected":false},"template":"","class_list":["post-251621","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-crohns-disease","biopharma-therapy-areas-gastrointestinal","biopharma-product-epidemiology","biopharma-date-950"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251621","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251621\/revisions"}],"predecessor-version":[{"id":284069,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251621\/revisions\/284069"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=251621"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}